Adam Simpson

Adam Simpson is the chief executive officer (CEO) of Icosavax. He has substantial life science operational and emerging company experience and has executed significant partnering and acquisition transactions. Previously, Adam was CEO of PvP Biologics, another spinout from University of Washington’s Institute for Protein Design (IPD), from company creation through its sale to Takeda. Prior to joining PvP Biologics, he was the president and chief operating officer of Cypher Genomics, a genome interpretation company focused on biomarker discovery to facilitate drug development, through its sale to Human Longevity, Inc. Prior to that, Adam was a cofounder and chief business officer of Meritage Pharma, a company developing treatments for upper gastrointestinal disorders, from company creation through its staged sale to Shire, and at Verus Pharmaceuticals, a company focused on treatments for asthma and anaphylaxis, where as general counsel he led its sale to AstraZeneca and Shionogi. He has been a cofounder of four additional life sciences companies that have either gone public or been acquired. Adam started his career as an attorney at Latham & Watkins. He holds a B.S. in biochemistry from the University of California, San Diego, and received his J.D. from the University of Minnesota Law School.